Announcements Trials
Browse Landscape

Phase

Phase 1 41Phase 2 34Phase 1/2 14Phase 3 13Phase NA 12Phase EARLY_PHASE1 3Phase 2/3 2Phase 4 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 3Head & Neck 3Tumor-Agnostic 2Other hematologic neoplasm 2Lymphoid 2CNS 2Thoracic 1Plasma cell 1Other 1Gynecologic 1Genitourinary 1

Conditions

Glioblastoma 2Recurrence 1Oligodendroglioma 1Astrocytoma 1

Interventions

Temozolomide 11Lomustine 6Radiotherapy 4Magnetic Resonance Spectroscopy 3Etoposide 3Carboplatin 3Bevacizumab 3vocimagene amiretrorepvec 2Vincristine 2Radiation 2Gefitinib 2veliparib 1trofosfamide 1trametinib 1tozuleristide 1tinostamustine 1regorafenib 1omburtamab I-131 1entrectinib 1dabrafenib 1cobimetinib 1carbon-11 acetate 1capmatinib 1antisecretory factor 1alectinib 1Vorinostat 1Vemurafenib 1Thiotepa 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Radiation × CNS × Clear all
NCT03970447 2026-05-15

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡